Chemomab Therapeutics Ltd. (CMMB)

NASDAQ: CMMB · Real-Time Price · USD

2.820

-0.212 (-6.99%)

At close: Sep 15, 2025, 4:00 PM EDT

2.800

-0.020 (-0.71%)

After-hours: Sep 15, 2025, 7:27 PM EDT

Chemomab Therapeutics Employees

Chemomab Therapeutics had 20 employees as of December 31, 2021.

Employees

20

Change

n/a

Growth

n/a

Revenue / Employee

n/a

Profits / Employee

-$591,300

Market Cap

14.59M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2021	20	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Thermo Fisher Scientific	125,000
Abbott Laboratories	114,000
AstraZeneca	92,900
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000

Employee Rankings

CMMB News

25 days ago - Chemomab Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
4 weeks ago - Chemomab Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
2 months ago - Chemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live'25 - GlobeNewsWire
3 months ago - Chemomab Reports Positive Feedback From Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing Cholangitis - GlobeNewsWire
3 months ago - Chemomab Announces New Patent Awards for Its First-in-Class Agent Nebokitug that is Positioned to Potentially Become the First Approved Drug for Primary Sclerosing Cholangitis - GlobeNewsWire
4 months ago - Chemomab Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
4 months ago - Chemomab Announces Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis in Distinguished Plenary Session at DDW 2025 - GlobeNewsWire
5 months ago - Chemomab Reports New Positive Clinical Data at EASL 2025 Supporting Nebokitug's Impact in Primary Sclerosing Cholangitis and Related Diseases - GlobeNewsWire